Drug Profile
PF 3732010
Alternative Names: PF-03732010; PF-3732010Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Cadherin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 28 Feb 2011 Discontinued - Phase-I for Solid tumours in Australia (IV)
- 28 Feb 2011 Discontinued - Phase-I for Solid tumours in South Korea (IV)
- 28 Feb 2011 Discontinued - Phase-I for Solid tumours in USA (IV)